

Regimen list

Regimen	Status
5-Fluorouracil (4 day) and mitoMYcin Chemoradiation - Version 4	Active
5-Fluorouracil (5 day) and mitoMYcin Chemoradiation - Version 2	Inactive
5-fluorouracil 225mg/m ² /day and Radiotherapy (RT)-Continuous infusion (7 day) - Version 6	Active
5-Fluorouracil and Folinic Acid Therapy-14 day Adj - Version 3	Active
5-Fluorouracil and Folinic Acid Therapy-14 day- Met - Version 2	Active
5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) - Version 1	Inactive
5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC 50) Therapy - Version 2	Inactive
Abiraterone 1000mg and Prednisolone 5mg - Version 2	Active
Abiraterone and Prednisolone - Version 4	Active
ABVD - Version 4	Active
Afatinib Monotherapy - Version 2	Inactive
Aflibercept and FOLFIRI -14 day - Version 1	Inactive
Anastrozole Monotherapy Adj - Version 3	Inactive
Anastrozole Monotherapy LA/M - Version 2	Inactive
Avelumab Monotherapy - Version 2	Inactive
Axitinib Monotherapy - Version 2	Active
azaCITIDine 100mg/m ² 5-day - Version 5	Active
azaCITIDine 75mg/m ² 5-2-2 - Version 5	Active
BEAM Autologous Transplant Conditioning Protocol - Version 1	Inactive
Bendamustine Monotherapy - Version 1	Inactive
Bevacizumab 10mg/kg - 14 days - Version 2	Inactive
Bevacizumab 15mg/kg - 21 days - Version 4	Active
Bevacizumab 5mg/kg -14 days - Version 2	Inactive
Bevacizumab 5mg/kg and FOLFIRI – 14 days - Version 2	Active
Bevacizumab 5mg/kg and Modified FOLFOX- 6 – 14 days - Version 4	Active
Bevacizumab 7.5mg/kg – 21 days - Version 4	Active
Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m ² Therapy- 21 day - Version 1	Active
Bevacizumab 7.5mg/kg, CARBOplatin(AUC5) and PACLitaxel 175mg/m ² - Version 2	Active
Bicalutamide - Version 1	Inactive
Bleomycin, Etoposide and CISplatin (BEP) - Version 1	Inactive
Bortezomib and Dexamethasone - Version 4	Active
Bortezomib Maintenance - 14 day - Version 3	Active
Bortezomib, Lenalidomide and Dexamethasone (RVD) - 21 day - Version 3	Inactive
Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day - Version 2	Active
Bortezomib, Melphalan & Prednisolone - Version 2	Inactive
Bortezomib, Thalidomide and Dexamethasone (VTD) Induction - Version 2	Inactive
Bosutinib Monotherapy - Version 1	Inactive
Brentuximab vedotin and Bendamustine - Version 1	Active
Brentuximab vedotin and ESHAP (BRESHAP) - Version 1	Active
Brentuximab vedotin and ICE - Version 3	Active
Brentuximab vedotin Monotherapy - Version 2	Active
Brigatinib - Version 2	Inactive
Busulfan,Cyclophosphamide – MAC – SIB - Version 2	Active
Busulfan,Cyclophosphamide,ATG Grafalon® – MAC – Mismatched Sibling Donor - Version 2	Active
Busulfan,Cyclophosphamide,ATG Grafalon® – MAC – Mismatched Unrelated Donor - Version 2	Active
Busulfan,Cyclophosphamide–MAC–MUD - Version 2	Active
Cabazitaxel and Prednisolone - Version 1	Inactive
Cabozantinib - Version 2	Inactive
Capecitabine 825mg/m ² and RT-7 day - Version 2	Active
Capecitabine and Oxaliplatin Therapy (XELOX) Adj - Version 3	Active
Capecitabine and Oxaliplatin Therapy (XELOX) Met - Version 3	Active
Capecitabine and RT – 7 day - Version 4	Active
Capecitabine and Temozolomide - Version 2	Active
Capecitabine Monotherapy Adj - Version 4	Active
Capecitabine Monotherapy LA/M - Version 4	Inactive

Regimen list

Regimen	Status
CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m ²) Weekly with Radiotherapy (RT) -5 weeks - Version 7	Active
CARBOplatin (AUC 2) Weekly with Radiotherapy (RT) - Version 6	Active
CARBOplatin (AUC 3), Etoposide (50mg/m ²) and Thoracic Radiotherapy (TRT) -28 day - Version 2	Active
CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m ² /day – 28 day - Version 6	Active
CARBOplatin (AUC 6) and PACLitaxel 200mg/m ² - Version 4	Inactive
CARBOplatin (AUC1.5) Chemoradiation - 7 days - Version 4	Active
CARBOplatin (AUC5) and Etoposide 100mg/m ² - 21 days - Version 8	Active
CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m ² followed by Dose Dense DOXorubicin Cyclophosphamide Therapy- Triple Negative Breast Cancer - Version 4	Active
CARBOplatin 70mg/m ² and 5-Fluorouracil 600mg/m ² with Radiotherapy - Version 1	Active
CARBOplatin and Oral Etoposide - 21days - Version 3	Active
CARBOplatin and vinORElbine Therapy-21 Day - Version 1	Inactive
CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m ² with Radiotherapy - Version 3	Active
CARBOplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m ² Therapy-28 day - Version 1	Inactive
CARBOplatin AUC4 Monotherapy-21 days - Version 3	Inactive
CARBOplatin AUC4 Monotherapy-28 days - Version 3	Active
CARBOplatin AUC5 and PACLitaxel 175mg/m ² Adj - Version 4	Active
CARBOplatin AUC5 and PACLitaxel 175mg/m ² Met - Version 3	Active
CARBOplatin AUC5 Monotherapy-21 days - Version 3	Active
CARBOplatin AUC5 Monotherapy-28 days - Version 3	Active
CARBOplatin AUC6 and PACLitaxel 175mg/m ² Adj - Version 4	Active
CARBOplatin AUC6 and PACLitaxel 175mg/m ² Met - Version 5	Active
CARBOplatin AUC6 Monotherapy-21 days - Version 5	Active
CARBOplatin AUC6 Monotherapy-28 days - Version 5	Active
CARBOplatin AUC7 and PACLitaxel 175mg/m ² Adj - Version 4	Active
CARBOplatin AUC7 and PACLitaxel 175mg/m ² Met - Version 4	Active
CARBOplatin AUC7.5 and PACLitaxel 175mg/m ² Adj - Version 7	Active
CARBOplatin AUC7.5 and PACLitaxel 175mg/m ² Met - Version 7	Active
Carfilzomib (27mg/m ² twice weekly), Lenalidomide and Dexamethasone (KRd) - 28 day - Version 3	Inactive
Carfilzomib and Dexamethasone (Kd) - 28 day - Version 3	Inactive
Carmustine,Etoposide,Cytarabine,Melphalan,Alemtuzumab RIC-SIB/MUD - Version 2	Active
Cetuximab - 7 day (12 weeks) - Version 4	Active
Cetuximab - 7 day (8 weeks) - Version 4	Active
Cetuximab (14 days) and FOLFIRI (14 days) - Version 1	Inactive
Cetuximab (14 days) and Irinotecan (14 days) - Version 2	Active
Cetuximab (7 days) and FOLFIRI (14 days) Therapy - Version 3	Inactive
Cetuximab (7 days) and Irinotecan (14 days) - Version 2	Active
Cetuximab (weekly), CARBOplatin AUC 5 and 5-Fluorouracil 1000mg/m ² /day - 21 day cycle - Version 8	Active
Cetuximab (weekly), CISplatin 100mg/m ² and 5-Fluorouracil 1000mg/m ² /day - 21 day cycle - Version 5	Inactive
CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and ONE dose gemtuzumab ozogamicin (for patients ≥1 year and >10kg and BSA ≥ 0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and THREE dose gemtuzumab ozogamicin (for patients ≥1 year and >10kg and BSA ≥ 0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and TWO dose Gemtuzumab Ozogamicin (<1 year or ≤10kg or BSA <0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 2 - FLA IDA (for HR patients <1 year or ≤10kg or BSA <0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 2 – FLA IDA (for HR patients ≥1 year and >10kg and BSA ≥0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 2 - mitoXANTRONE, Cytarabine (for non HR patients <1 year or ≤10kg or BSA <0.5m ²) - Version 1	Inactive
CHI AML MyeChild Course 2 - mitoXANTRONE, Cytarabine (for non HR patients ≥1 year and >10kg and BSA ≥0.5m ²) - Version 1	Inactive

Regimen list

Regimen	Status
CHI AML MyeChild Course 3 - FLA (for HR patients ≥ 1 year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$) - Version 1	Inactive
CHI AML MyeChild Course 3 - FLA (for HR patients <1 year or $\leq 10\text{kg}$ or $\text{BSA} < 0.5\text{m}^2$) - Version 1	Inactive
CHI AML MyeChild Course 3 - FLA IDA (for IR and HR patients <1 year or $\leq 10\text{kg}$ or $\text{BSA} < 0.5\text{m}^2$) - Version 1	Inactive
CHI AML MyeChild Course 3 - FLA IDA (for IR and HR patients ≥ 1 year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$) - Version 1	Inactive
CHI AML MyeChild Course 3 and 4 - FLA (for SR patient ≥ 1 year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$) - Version 1	Inactive
CHI AML MyeChild Course 3 and 4 - FLA (for SR patients <1 year or $\leq 10\text{kg}$ or $\text{BSA} < 0.5\text{m}^2$) - Version 1	Inactive
CHI AML Myechild Course 3 and 4 - HD Cytarabine (for SR patients <1 year or $\leq 10\text{kg}$ or $\text{BSA} < 0.5\text{m}^2$) - Version 1	Inactive
CHI AML Myechild Course 3 and 4 - HD Cytarabine (for SR patients ≥ 1 year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$) - Version 1	Inactive
CHI AML MyeChild Course 4 - High Dose Cytarabine (for IR patients <1 year or $\leq 10\text{kg}$ or $\text{BSA} < 0.5\text{m}^2$) - Version 1	Inactive
CHI AML MyeChild Course 4 - High Dose Cytarabine (for IR patients ≥ 1 year and $>10\text{kg}$ and $\text{BSA} \geq 0.5\text{m}^2$) - Version 1	Inactive
CHI ES VDC/IE Induction Euro Ewing 2012 - Version 1	Inactive
Chlorambucil $10\text{mg}/\text{m}^2$ - Version 2	Active
CHOEP – 21 days - Version 2	Active
CISplatin ($100\text{mg}/\text{m}^2$) with Radiotherapy (RT) - 21 day - Version 7	Active
CISplatin ($40\text{mg}/\text{m}^2$) Weekly with Radiotherapy (RT) (5 cycles) - Version 8	Active
CISplatin ($40\text{mg}/\text{m}^2$) Weekly with Radiotherapy (RT) (6 cycles) - Version 7	Active
CISplatin ($50\text{mg}/\text{m}^2$) and Etoposide ($50\text{mg}/\text{m}^2$) and Thoracic Radiotherapy (TRT) -28 day - Version 4	Active
CISplatin ($50\text{mg}/\text{m}^2$) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel ($175\text{mg}/\text{m}^2$) – Endometrial Cancer - Version 1	Active
CISplatin ($75\text{mg}/\text{m}^2$) + Etoposide - 21 day - Version 6	Active
CISplatin ($75\text{mg}/\text{m}^2$) + Etoposide ($100\text{mg}/\text{m}^2$) +Thoracic Radiotherapy (TRT) -21 day - Version 6	Active
CISplatin $75\text{mg}/\text{m}^2$ and 5-Fluorouracil Chemoradiation - Herskovic Regimen - Version 4	Active
CISplatin and 5-Fluorouracil- 28 day cycle - Version 1	Inactive
CISplatin and Capecitabine Adjuvant Chemoradiation - Version 1	Inactive
CISplatin, 5-Fluorouracil and Radiation Therapy - Version 1	Active
CISplatin, Methotrexate and vinBLASTine (CMV) - Version 1	Inactive
Cladribine $0.14\text{mg}/\text{kg}$ Day 1 to 5 Therapy - Version 2	Active
Cladribine $0.14\text{mg}/\text{kg}$ Weekly - Version 2	Active
Cladribine 5 day and riTUXimab - Version 1	Inactive
Cladribine Weekly and riTUXimab - Version 1	Inactive
Crizotinib Monotherapy - Version 4	Inactive
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Adj - Version 4	Active
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Met - Version 2	Inactive
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 day Adj - Version 1	Inactive
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Met - Version 1	Inactive
Cyclophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Met - Version 1	Inactive
Cyclophosphamide(Oral) Methotrexate and 5-Fluorouracil (CMF) Adj - Version 1	Inactive
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day - Version 3	Inactive
Cyclophosphamide, DOXOrubicin, vinCRISTine and prednisoLONE (CHOP) Therapy– 21 days - Version 2	Active
Cyclophosphamide,Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor - Version 2	Active
Cyclophosphamide,Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor - Version 1	Active
Cyclophosphamide,Total Body Irradiation (TBI)–MAC–MUD - Version 2	Active
Cyclophosphamide,Total Body Irradiation (TBI)–MAC–SIB - Version 2	Active

Regimen list

Regimen	Status
DA (50/100) (3+8) Course 2 Induction (AML-17) - Version 4	Active
DA(60/100) 3+10: Course 1 Induction (AML-17) - Version 5	Active
Dabrafenib Monotherapy - Version 3	Active
Dacarbazine (1.2g/m ²) -21 day - Version 2	Inactive
DACTINomycin - Version 1	Inactive
Daratumumab (IV), Bortezomib and Dexamethasone Therapy - Version 1	Inactive
Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy - Version 1	Active
Daratumumab (SC 1800mg), Bortezomib and Dexamethasone - Version 1	Active
Daratumumab Monotherapy - Version 3	Active
Daratumumab SC Monotherapy - Version 2	Active
Decitabine Monotherapy - Version 1	Inactive
Degarelix-28 day - Version 2	Active
Dexamethasone, ritUXImab and Cyclophosphamide (DRC) - Version 1	Inactive
DOCEtaxel /Cyclophosphamide (TC)-21 day - Version 5	Active
DOCEtaxel 75mg/m ² –Prednisolone Combination - Version 1	Inactive
DOCEtaxel Monotherapy 100mg/m ² - 21 day - Version 2	Inactive
DOCEtaxel Monotherapy 50mg/m ² – 14 day cycle - Version 4	Inactive
DOCEtaxel Monotherapy 75mg/m ² – 21 day cycle - Version 2	Active
DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days - Version 6	Active
DOCEtaxel, CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy - Version 2	Inactive
DOCEtaxel,CISplatin, 5-Fluorouracil and Radiotherapy - Version 2	Inactive
Dose Adjusted R-EPOCH - Version 3	Inactive
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day (DD AC-T) - Version 7	Active
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) - Version 2	Active
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day (DD AC-T) - Version 5	Active
Dose Dense DOXOrubicin, Cyclophosphamide (AC60/600) 14 day followed by weekly PACLitaxel and Trastuzumab Therapy (DD AC-TH) - Version 3	Active
DOXOrubicin (25mg/m ² /day) and CISplatin (100mg/m ²)-21 day cycle - Version 1	Inactive
DOXOrubicin (60) and Ifosfamide - Version 1	Inactive
DOXOrubicin (60mg/m ²) - Version 3	Active
DOXOrubicin (75) and Ifosfamide - Version 2	Inactive
DOXOrubicin 50mg/m ² /Docetaxel 75mg/m ² (AT 50/75)-21 day cycle - Version 1	Inactive
DOXOrubicin 75mg/m ² Monotherapy - Version 2	Active
DOXOrubicin, and Cyclophosphamide (AC 60/600) - 21 day - Version 1	Inactive
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab (AC-TH) - Version 1	Inactive
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) - Version 2	Inactive
Durvalumab Monotherapy 10mg/Kg-14 Day - Version 2	Active
Durvalumab Monotherapy 1500mg – 28 Day - Version 1	Active
EMA/CO Therapy (Etoposide, Methotrexate, DACTINomycin, Cyclophosphamide, vinCRISTine) - Version 1	Inactive
Encorafenib and Binimetinib - Version 1	Inactive
Enzalutamide Monotherapy - Version 3	Active
EP/EMA Therapy (Etoposide CISplatin/Etoposide Methotrexate DACTINomycin) - Version 2	Inactive
Epirubicin 75 + Cyclophosphamide (EC75) -21 day - Version 1	Inactive
Epirubicin 90 + Cyclophosphamide (EC90)-21 day - Version 1	Inactive
EpiRUBicin, CISplatin and 5-Fluorouracil (ECF) - ADJ -21 day - Version 1	Inactive
EpiRUBicin, CISplatin and 5-Fluorouracil (ECF) -21 day LA/M - Version 1	Inactive
EpiRUBicin, Oxaliplatin and 5-Fluorouracil (EOF)- 21 day - Version 1	Inactive
Epirubicin, Oxaliplatin and Capecitabine (EOX) -21 day - Version 2	Inactive
EriBULin Monotherapy - Version 3	Active
Erlotinib Monotherapy - Version 3	Active
Escalated Dose BEACOPP 21 day - Version 2	Inactive
ESHAP - Version 3	Active

Regimen list

Regimen	Status
Etoposide and CISplatin 20mg/m ² (EP) 5 day - Version 3	Inactive
Everolimus and Exemestane - Version 2	Active
Everolimus Monotherapy - Version 2	Active
Exemestane Monotherapy Adj - Version 2	Active
Exemestane Monotherapy Met - Version 2	Active
FLAG Therapy - Version 3	Inactive
FLAG: Ida 8mg/m ² - Version 6	Active
FLOT -14 day NAdj - Version 5	Active
FLOT-14 day Adj - Version 5	Active
FLOX - Version 1	Active
Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL - Version 2	Active
Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL - Version 1	Active
Fludarabine, cyclophosphamide and ritUXimab (FC IV+R) - Version 3	Active
Fludarabine, cyclophosphamide and ritUXimab (FC Oral +R) - Version 1	Active
Fludarabine, Busulfan, ATG Grafalon® – RIC – MUD - Version 1	Active
Fludarabine, Busulfan, ATG Grafalon® – RIC –SIB - Version 2	Active
Fludarabine, Melphalan, Alemtuzumab-RIC-MUD - Version 1	Active
Fludarabine, Melphalan, Alemtuzumab-RIC-SIB - Version 1	Active
FOLFIRI 14 day - Version 4	Active
FOLFIRINOX - Version 2	Inactive
FOLFOX-4 14 day Adj - Version 5	Inactive
FOLFOX-4 14 day Met - Version 3	Inactive
FOLFOXIRI - Version 3	Active
Fulvestrant - Version 2	Active
Gefitinib Monotherapy - Version 1	Inactive
Gemcitabine (1000mg/m ²) and RT - Version 2	Inactive
Gemcitabine (1000mg/m ²) and CARBOplatin (AUC 4) - 21 day - Version 4	Inactive
Gemcitabine (1000mg/m ²) and CARBOplatin (AUC 5)- 21 day - Version 3	Active
Gemcitabine (1000mg/m ²) and CISplatin (25mg/m ²) - 21 day - Version 2	Inactive
Gemcitabine (1000mg/m ²) and CISplatin (70mg/m ²) Therapy- 28 day - Version 2	Active
Gemcitabine (1000mg/m ²) Monotherapy - 28 day Adj - Version 3	Inactive
Gemcitabine (1000mg/m ²) Monotherapy - 28 day Met - Version 3	Inactive
Gemcitabine (1000mg/m ²) Monotherapy - 56 day - Version 2	Inactive
Gemcitabine (1000mg/m ²), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg - 21 day - Version 3	Inactive
Gemcitabine (1250mg/m ²) and CISplatin (75mg/m ²)- 21 day - Version 2	Active
Gemcitabine (1250mg/m ²) and CISplatin (80mg/m ²) - 21 day - Version 1	Inactive
Gemcitabine (1250mg/m ²) Monotherapy - 21 day - Version 1	Inactive
Gemcitabine (400mg/m ²) and RT - Version 2	Inactive
Gemcitabine (600mg/m ²) and RT-7 day - Version 3	Active
Gemcitabine and CARBOplatin (AUC2) - 21 days - Version 3	Active
Gemcitabine and DOCEtaxel - 21 day - Version 2	Active
Goserelin 10.8mg-12 weeks - Version 2	Active
Goserelin 3.6mg-28 day - Version 1	Active
High Dose Cytarabine - Version 3	Active
High Dose Melphalan Conditioning for Autologous Stem Cell Transplant - Version 1	Active
Hypersensitivity - As Required Medications - Version 1	Active
Ibrutinib Therapy CLL / Waldenström's macroglobulinaemia - Version 2	Active
Ibrutinib Therapy Mantle Cell Lymphoma - Version 2	Active
ICE (Ifosfamide, CARBOplatin and Etoposide) - Version 3	Active
Idelalisib Monotherapy - Version 1	Active
Imatinib - GIST Adj - Version 2	Inactive
Imatinib - GIST Met - Version 2	Active
Inotuzumab ozogamicin Monotherapy - Version 1	Inactive
Intermediate Dose Cytarabine - Version 4	Active
Intrathecal Methotrexate for CNS prophylaxis in GTN - Version 1	Inactive
Intravenous Vinorelbine Monotherapy - 21 day - Version 3	Active
Ipilimumab Monotherapy - Version 4	Active

Regimen list

Regimen	Status
Irinotecan Monotherapy - 21 days - Version 2	Inactive
Ixazomib, Lenalidomide and Dexamethasone- 28 day - Version 2	Active
LEAM Autologous Transplant Conditioning Regimen - Version 3	Inactive
Lenalidomide 25mg and Dexamethasone- 28 day - Version 1	Active
Lenvatinib -DTC Therapy - Version 3	Active
Letrozole Monotherapy Adj - Version 4	Active
Letrozole Monotherapy Met - Version 3	Inactive
Letrozole Monotherapy NAdj - Version 3	Active
Leuporelin 11.25mg-12 weeks - Version 2	Active
Leuporelin 22.5mg-12 weeks - Version 2	Active
Leuporelin 3.75mg-28 days - Version 1	Active
Leuporelin 30mg-24 weeks - Version 1	Active
Leuporelin 45mg-24 week - Version 2	Active
Leuporelin 7.5mg-28 day - Version 1	Active
Methotrexate 8 day Charing Cross Regimen - Version 1	Inactive
Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -14 Days - Version 1	Inactive
Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days Adj - Version 1	Inactive
Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days Met - Version 1	Inactive
Methotrexate,vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days NAdj - Version 1	Inactive
Mifamurtide - Version 1	Inactive
Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone – Weekly Therapy - Version 3	Active
Modified FOLFIRINOX - Version 1	Inactive
Modified FOLFOX-6 14 day Adj - Version 8	Active
Modified FOLFOX-6 14 day Met - Version 7	Active
Modified FOLFOX-6 Chemoradiation-14 day - Version 2	Inactive
Modified Roswell Park (Fluorouracil 500mg/m ² and Folinic Acid 50mg weekly x 6) Regimen Adj - Version 2	Inactive
Modified Roswell Park (Fluorouracil 500mg/m ² and Folinic Acid 50mg weekly x 6) Regimen Met - Version 2	Inactive
Nab-Paclitaxel (Abraxane) and Gemcitabine - 28 day - Version 2	Inactive
Nab-PACLitaxel (Abraxane®) Monotherapy– 21 day - Version 1	Inactive
Neoadjuvant DOCETaxel, CISplatin,5-Fluorouracil and Chemoradiation and Surgery - Version 3	Inactive
Nivolumab 1mg/kg Ipilimumab 3mg/kg - Version 3	Active
Nivolumab 3mg/kg with Ipilimumab 1mg/kg - Version 2	Active
Nivolumab Monotherapy 240mg - 14 days (6 cycles) - Version 4	Active
Nivolumab Monotherapy 240mg - 14 days Adj (26 cycles) - Version 3	Active
Nivolumab Monotherapy 480mg-28 days (3 cycles) - Version 3	Active
Nivolumab Monotherapy 480mg-28 days Adj (13 cycles) - Version 3	Active
Obinutuzumab and Bendamustine-28 day cycle - Version 1	Active
Obinutuzumab and Chlorambucil - Version 2	Active
Obinutuzumab and CHOP-21 day - Version 2	Active
Obinutuzumab Cyclophosphamide vinCRISTine and prednisoLONE (O-CVP)-21 days - Version 2	Active
Obinutuzumab Maintenance Therapy-56 day - Version 2	Active
Olaparib (Capsule) Monotherapy - Version 1	Inactive
Oral Etoposide - Version 2	Inactive
Oral Vinorelbine Monotherapy-7 days - Version 4	Active
Osimertinib Monotherapy - Version 1	Active
PACLitaxel (80) and Trastuzumab-7 day (12 weeks) - Version 2	Inactive
PACLitaxel 80mg/m ² Day 1, 8 and 15 Monotherapy-28 Day - Version 2	Active
PACLitaxel Monotherapy 80mg/m ² Day 1, 8, 15 and 22 – 28 Day - Version 8	Active
PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) - Version 1	Inactive
Palbociclib-28 day - Version 3	Active
Panitumumab 6mg/kg - Version 3	Active
Panitumumab 6mg/kg and FOLFIRI -14 day - Version 3	Inactive
Panitumumab 6mg/kg and Modified FOLFOX-6 – 14 day - Version 4	Inactive

Regimen list

Regimen	Status
Pegylated Liposomal DOXOrubicin 20 mg/m ² (CAELYX)® 21 days - Version 2	Active
Pegylated Liposomal DOXOrubicin 50mg/m ² (CAELYX) 28 days - Version 4	Active
Pembrolizumab 200mg Monotherapy (4 cycles) - Version 6	Active
Pembrolizumab 200mg Monotherapy Adj (18 cycles) - Version 4	Active
Pembrolizumab 400mg Monotherapy (2 cycles) - Version 6	Active
Pembrolizumab 400mg Monotherapy Adj (9 cycles) - Version 4	Active
Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) - Version 3	Active
Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) - Version 1	Inactive
PEMEtrexed and CARBOplatin - Version 5	Active
PEMEtrexed and CISplatin - Version 2	Active
PEMEtrexed Monotherapy - Version 2	Active
Pertuzumab and Trastuzumab and Chemotherapy - 21 day cycle Adj - Version 3	Active
Pertuzumab and Trastuzumab and Chemotherapy - 21 day cycle NAdj - Version 3	Active
Pertuzumab and Trastuzumab and DOCEtaxel Therapy - 21 day - Version 4	Active
Pertuzumab Trastuzumab and Vinorelbine - Version 3	Active
Pertuzumab Trastuzumab and Weekly PACLitaxel - 21 day cycle - Version 4	Active
Pixantrone Therapy - Version 1	Inactive
Pomalidomide and Dexamethasone - Version 3	Active
Procarbazine Lomustine and VinCRISTine (PCV) - Version 2	Inactive
QUASAR (Modified) Fluorouracil (370mg/m ²) and Folinic Acid (50mg) Weekly Adj - Version 4	Inactive
QUASAR (Modified) Fluorouracil (370mg/m ²) and Folinic Acid (50mg) Weekly Met - Version 3	Inactive
R- miniCHOP - 21 days - Version 2	Inactive
R-CEOP – 21 days - Version 1	Inactive
R-CHOP - 21 days - Version 6	Active
R-CHOP-14 days - Version 7	Active
R-CODOX-M (Patients >65 years) - Version 1	Inactive
R-CODOX-M (Patients ≤65yrs) - Version 1	Inactive
R-CVP – 21 days riTUXimab, Cyclophosphamide vinCRISTine and Prednisolone - Version 2	Active
R-DHAP - Version 1	Active
Regorafenib Monotherapy - Version 3	Inactive
R-ESHAP - Version 5	Active
R-Gemcitabine (1000mg/m2) Oxaliplatin - 14 day - Version 1	Inactive
Ribociclib-28 day - Version 1	Active
R-ICE (RiTUXimab), Ifosfamide, CARBOplatin and Etoposide) - Version 4	Active
RiTUXimab (S/C 1400mg) Maintenance - 56 day - Version 2	Active
RiTUXimab (S/C 1400mg) Maintenance - 84 day - Version 2	Active
RiTUXimab 375 mg/m ² - 7 day - Version 2	Active
riTUXimab 375 mg/m ² Combination Therapy-21 day - Version 2	Active
RiTUXimab 375 mg/m ² Maintenance Therapy- 56 day - Version 3	Active
RiTUXimab 375mg/m ² - Follicular Lymphoma (every 2 months) - Version 2	Inactive
RiTUXimab 375mg/m ² - Follicular Lymphoma (every 3 months) - Version 2	Inactive
RiTUXimab 375mg/m ² - Follicular Lymphoma (once weekly for four weeks) - Version 2	Inactive
RiTUXimab 375mg/m ² Maintenance-84 day - Version 2	Active
RiTUXimab and Bendamustine - Version 2	Inactive
riTUXimab S/C, (R-CHOP) Therapy– 21 Days - Version 1	Active
riTUXimab** Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP) - Version 1	Inactive
Ruxolitinib Monotherapy - Version 1	Inactive
SORafenib - Version 2	Active
SUNitinib 37.5mg - Version 1	Active
SUNitinib 50mg - Version 1	Active
Tamoxifen Monotherapy Adj - Version 1	Inactive
Tamoxifen Monotherapy Met - Version 1	Inactive
Temozolomide Recurrent Therapy - Version 2	Active
Temozolomide with Radiotherapy (RT) and Adjuvant Therapy - Version 2	Active

Regimen list

Regimen	Status
Temozolomide with Radiotherapy (RT) and Adjuvant Therapy - Patients greater than 65 years - Version 2	Active
Temsirolimus Monotherapy - Version 2	Active
Topotecan Monotherapy – 5 day - Version 2	Inactive
Topotecan Monotherapy – Weekly - Version 2	Inactive
Topotecan Oral Monotherapy - Version 1	Inactive
Trabectedin and Pegylated Liposomal DOXOrubicin (PLD) - Version 2	Inactive
Trabectedin Monotherapy - Version 1	Inactive
Trametinib and Dabrafenib- Met - Version 1	Active
Transcription only. See original prescription. - Version 1	Active
Trastuzumab (IV) Monotherapy - 21 days Adj - Version 4	Active
Trastuzumab (IV) Monotherapy - 7 days - Version 3	Active
Trastuzumab (IV) Monotherapy- 21 days Met - Version 4	Active
Trastuzumab 5-Fluorouracil and CISplatin - 21 days - Version 3	Active
Trastuzumab Emtansine (Kadcyla®) - 21 days - Version 3	Active
Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer - Version 5	Active
Trastuzumab Subcutaneous 21 days - Early Breast Cancer - Version 5	Active
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation - Version 1	Inactive
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction - Version 1	Inactive
Triptorelin 11.25mg-12 weeks - Version 1	Active
Triptorelin 22.5mg-24 weeks - Version 1	Active
Triptorelin 3mg-28 day - Version 1	Active
Two Day Etoposide CISplatin (EP) - Version 1	Inactive
Vandetanib Therapy - Version 1	Inactive
Vemurafenib Monotherapy - Version 2	Inactive
Venetoclax Monotherapy - Version 2	Active
VinBLASTine and Methotrexate - Version 1	Inactive
Vinorelbine 30 (Day 1,8,15) and CISplatin 80 (Day1) Therapy- 21 day - Version 1	Inactive
Vinorelbine and CISplatin Therapy - 28 day - Version 1	Inactive
Vismodegib Monotherapy - Version 3	Active
Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m ² with Radiotherapy - Version 7	Active
Zoledronic Acid Monotherapy - Version 2	Active